In the high-stakes world of clinical development, the comparator is more than just a reference it is the “Gold Standard” benchmark against which all innovation is measured. Proving that an Investigational Medicinal Product (IMP) is superior or non-inferior to existing therapies is the cornerstone of Phase III trials and a critical requirement for regulators like the EMA and FDA.
However, the path from sourcing a comparator to regulatory approval is fraught with analytical hurdles. Successful IMPD or IND submissions depend on more than just “testing”; they require a deep, forensic understanding of the innovator’s profile.
The Analytical “Art” of Blinding
We serve as the essential Quality Gatekeeper. Our roleis to provide the rigorous analytical validation that ensures a physical blind (whether single, double, or the data-secure triple-blind) does not compromise drug integrity. From guiding on selecting the right HPMC or Gelatin shells to sophisticated packaging solutions like “Blister Blinding”, we ensure the “Art of Blinding” remains scientifically sound.
Overcoming the f_2 Challenge
The most significant technical bottleneck often arises during Comparative Dissolution. Over-encapsulation naturally introduces a physical lag time that can artificially lower the f_2 similarity factor, leading to potential regulatory panic.
Our approach transforms this challenge into a narrative of confidence. By utilising mathematical lag-time corrections, bio-relevant media, and USP Tier-2 testing, we isolate the capsule effect from true drug performance. With 21 years of expertise, we don’t just report a failure; we provide the scientific justification required to keep clinical timelines on track.
At Eurofins BioPharma Product Testing in Dungarvan, we find the truth in the baseline, ensuring your comparator data is as robust as your innovation.
Contact us or visit our webpage to find out more about our comparator services.
Request access to our on-demand webinar: Comparator Testing: Ensuring Product Integrity and Regulatory Compliance in Clinical Development
To find out more about Comparator Studies Matter in Drug Development, watch our video.